Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover extension study of iptacopan in adults with primary IgA nephropathy
2020-002200-40Phase 3Active
- Sponsor
- Novartis
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of iptacopan. Started Jun 2021; status: active.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2020-002200-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002200-40.